Differential Diagnosis for Mobile Subcutaneous Mass

Primary Benign Considerations

Lipomas are the most frequently encountered mobile subcutaneous masses, presenting as soft, well-defined, mobile masses that indent when depressed with biopsy forceps, with a frequency of 96% of superficial masses, according to the American College of Radiology 1.
Epidermoid cysts represent another common benign entity, with ultrasound demonstrating high sensitivity (94.1%) and specificity (99.7%) for superficial soft tissue masses, including this diagnosis, as reported by the American College of Radiology 1, 2.
Vascular malformations can present as mobile subcutaneous masses and may contain phleboliths visible on radiographs, which are diagnostic when present, as noted by the American College of Radiology 1.

Atypical lipomatous tumors (ALT)/well-differentiated liposarcoma must be distinguished from simple lipomas, as ALT has a propensity for local recurrence despite being mobile, with MDM-2 gene amplification detected by fluorescence in-situ hybridization on core needle biopsy being a key differentiating feature, according to the British Journal of Cancer 3, 4.
Desmoid tumors (aggressive fibromatosis) are characterized by local infiltration rather than distant metastasis and should be considered in the differential, as stated by the National Comprehensive Cancer Network 5.

Dermatofibrosarcoma protuberans (DFSP) arises in skin or superficial subcutaneous tissues and requires wide surgical excision, as recommended by the British Journal of Cancer 3, 4.
Pleomorphic dermal sarcomas can present as large subcutaneous masses and should be diagnosed preoperatively by core/punch biopsy with surgery planned to accommodate possible postoperative radiotherapy, according to the British Journal of Cancer 3, 4.

Initial imaging must begin with radiographs to identify calcifications, bone involvement, or intrinsic fat, with overall positive findings in 62% of cases, as reported by the American College of Radiology 1, 2, 6.
Ultrasound is the next appropriate step for small superficial lesions, with sensitivity of 94.1% and specificity of 99.7% for superficial soft tissue masses, as noted by the American College of Radiology 1, 2.
MRI without and with contrast is indicated when ultrasound findings are inconclusive, the mass is deep-seated, or there are atypical features requiring further characterization, as recommended by the American College of Radiology 2, 6.

Core needle biopsy under image guidance is the standard approach for suspicious masses requiring histopathological diagnosis, with multiple core samples taken to maximize diagnostic yield, as stated by the National Comprehensive Cancer Network and the American College of Radiology 2, 5, 6.
Excisional biopsy may be more practical for small subcutaneous lesions less than 5 cm or when imaging characteristics are indeterminate, as noted by the American College of Radiology 2, 6.

Physical examination alone correctly identifies only about 85% of soft tissue tumors, making imaging mandatory, as reported by the American College of Radiology 2.
Any mass with firm consistency, irregular margins, size >5 cm, rapid growth, or deep location requires referral to a specialized sarcoma center with multidisciplinary team evaluation before definitive treatment, as recommended by the National Comprehensive Cancer Network and the British Journal of Cancer 3, 2, 5.

Overlying skin abnormalities—such as dimpling, discoloration, or other cutaneous changes—should be explicitly recorded in the clinical note. American College of Radiology recommendation. 7

Plain radiographs are the first‑line imaging study; they reveal calcifications, bone involvement, or intrinsic fat in approximately 62 % of soft‑tissue masses. American College of Radiology guideline. 8
For small, superficial lesions, ultrasound should be the next imaging modality, offering 94.1 % sensitivity and 99.7 % specificity for characterizing the mass. American College of Radiology guideline. 8

Physical examination alone correctly identifies only 85 % of soft‑tissue tumors; therefore, imaging must be planned and documented to avoid missed or mischaracterized lesions. American College of Radiology recommendation. 8

Documentation should state that a biopsy is deferred until appropriate imaging is completed, because premature biopsy can compromise definitive surgical management if the lesion proves to be a sarcoma. American College of Radiology guidance. [8][9]

The exact anatomic location of the mass (e.g., thoracic, lumbar, paraspinal) must be specified in the record, as location influences the differential diagnosis and subsequent management pathway. American College of Radiology recommendation. [8][9]